1 Meta-narrative review of molecular methods for diagnosis and monitoring of multidrug-resistant tuberculosis treatment in adults.

2 fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems

3 drug-resistant tuberculosis in children and adolescents in the republic of sakha (yakutia)

4 Prevalence, risk and genetic characteristics of drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China

5 Plasma indoleamine 2,3-dioxygenase activity as a potential biomarker for early diagnosis of multidrug-resistant tuberculosis in tuberculosis patients

6 Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China

7 Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China

8 Drug resistance profiles and trends in drug-resistant tuberculosis at a major hospital in Guizhou Province of China

9 Identifying differentially expressed long non-coding RNAs in PBMCs in response to the infection of multidrug-resistant tuberculosis

10 Association between tobacco smoking and drug-resistant tuberculosis

11 Second-line anti-tuberculosis drug resistance testing in Ghana identifies the first extensively drug-resistant tuberculosis case

12 Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis

13 Determinants of multidrug-resistant tuberculosis in Addis Ababa, Ethiopia

14 Genotypic distribution of multidrug-resistant and extensively drug-resistant tuberculosis in northern Thailand

15 Risk factors for multidrug-resistant tuberculosis among tuberculosis patients: a case-control study

16 Molecular detection of multidrug-resistant tuberculosis among smear-positive pulmonary tuberculosis patients in Jigjiga town, Ethiopia

17 New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid

18 Treatment of drug-resistant tuberculosis

19 Multidrug and extensively drug-resistant tuberculosis from a general practice perspective

20 Prevalence, risk and genetic characteristics of drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China

21 Prevalence, risk and genetic characteristics of drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China

22 Plasma indoleamine 2,3-dioxygenase activity as a potential biomarker for early diagnosis of multidrug-resistant tuberculosis in tuberculosis patients

23 Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China

24 Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China

25 Drug resistance profiles and trends in drug-resistant tuberculosis at a major hospital in Guizhou Province of China

26 Identifying differentially expressed long non-coding RNAs in PBMCs in response to the infection of multidrug-resistant tuberculosis

27 Association between tobacco smoking and drug-resistant tuberculosis

28 Second-line anti-tuberculosis drug resistance testing in Ghana identifies the first extensively drug-resistant tuberculosis case

29 Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis

30 Determinants of multidrug-resistant tuberculosis in Addis Ababa, Ethiopia

31 Genotypic distribution of multidrug-resistant and extensively drug-resistant tuberculosis in northern Thailand

32 Risk factors for multidrug-resistant tuberculosis among tuberculosis patients: a case-control study

33 Molecular detection of multidrug-resistant tuberculosis among smear-positive pulmonary tuberculosis patients in Jigjiga town, Ethiopia

34 New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid

35 Treatment of drug-resistant tuberculosis

36 Multidrug and extensively drug-resistant tuberculosis from a general practice perspective

37 Comparison of Serum Potassium, MagnEsium, and Calcium Levels between Kanamycin and Capreomycin-BASEd Regimen-Treated MultiDrug-Resistant TuBerculosis Patients in Bandung (CEASE MDR-TB): A Retrospective Cohort Study

38 [Control and management strategies in multidrug-resistant tuberculosis: literature reviewEstrategias de control y atención de la tuberculosis multirresistente: una revisión de la literatura].

39 [Multidrug-resistant tuberculosis: A management problem that weighs heavily on the University Hospitals of Strasbourg].

40 Tackling drug-resistant tuberculosis: we need a critical synergy of product and process innovations.

41 Multidrug-resistant tuberculosis.

42 Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005-2015.

43 The burden of latent multidrug-resistant tuberculosis.

44 Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling.

45 A nationwide study of multidrug-resistant tuberculosis in Portugal 2014-2017 using epidemiological and molecular clustering analyses.

46 Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres.

47 Frequency of the Mycobacterium tuberculosis RD genotype and its association with multidrug-resistant tuberculosis.

48 Multidrug-resistant tuberculosis (MDR-TB): Epidemiology, mechanisms of drug resistance

49 Multidrug-resistant tuberculosis (MDR-TB): Epidemiology, prevention and treatment

50 Análise comparativa entre tuberculose multirresistente e tuberculose extensivamente resistente - Epidemiologia e factores preditivos Comparative analysis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis - Epidemiology and predictive factors

51 Multidrug-resistant tuberculosis

52 Drug-resistant tuberculosis in eastern Europe and central Asia: a time-series analysis of routine surveillance data.

53 Evaluation of the QuantaMatrix Multiplexed Assay Platform for Molecular Diagnosis of Multidrug- and Extensively Drug-Resistant Tuberculosis Using Clinical Strains Isolated in Myanmar

54 Estimating treatment importance in multidrug-resistant tuberculosis using Targeted Learning: An observational individual patient data network meta-analysis.

55 [Survival time and influencing factors in multidrug-resistant tuberculosis patients in Wuhan, 2006-2014].

56 Drug-resistant tuberculosis in HIV-infected patients in a national referral hospital, Phnom Penh, Cambodia

57 [Loss to follow-up in patients treated for multidrug-resistant tuberculosis in EcuadorA Perda de seguimento de pacientes tratados para tuberculose multirresistente a medicamentos no Equador].

58 Drug-Resistant Tuberculosis – Diagnosis, Treatment, Management and Control: The Experience in Thailand

59 Outcomes of Community-Based Systematic Screening of Household Contacts of Patients with Multidrug-Resistant Tuberculosis in Myanmar.

60 Gridlock from diagnosis to treatment of multidrug-resistant tuberculosis in Tanzania: Low accessibility of molecular diagnostic services and lack of healthcare worker empowerment in 28 districts of 5 high burden TB regions with mixed methods evaluation

61 Prevalence of Pre-Extensively Drug-Resistant Tuberculosis (Pre XDR-TB) and Extensively Drug-Resistant Tuberculosis (XDR-TB) among pulmonary Multidrug Resistant Tuberculosis (MDR-TB) at a tertiary care center in Mumbai

62 Genome sequence of Mycobacterium yongonense RT 955-2015 isolate from a patient misdiagnosed with multidrug-resistant tuberculosis: First clinical detection in Tanzania.

63 Serum proteins TGFBI, PCSK9, and CCL14 are potential biomarkers for different traditional Chinese medicine syndromes of multidrug-resistant tuberculosis.

64 Sequential analysis as a tool for detection of amikacin ototoxicity in the treatment of multidrug-resistant tuberculosis.

65 Investigating spillover of multidrug-resistant tuberculosis from a prison: a spatial and molecular epidemiological analysis

66 Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

67 Social Mixing and Clinical Features Linked With Transmission in a Network of Extensively Drug-resistant Tuberculosis Cases in KwaZulu-Natal, South Africa

68 Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades

69 applicability of the shorter ‘bangladesh regimen’ in high multidrug-resistant tuberculosis settings

70 the role of process analysis and expert consultation in implementing an electronic medical record solution for multidrug-resistant tuberculosis

71 t cell cytokine responses in peripheral blood mononuclear cells from patients with multidrug-resistant tuberculosis following stimulation with proteins purified from mycobacterium tuberculosis mdr clinical isolates

72 prevalence of resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients in viet nam, 2011

73 minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: an integrated approach for multidrug-resistant tuberculosis

74 rifabutin: is it useful in the treatment of multidrug-resistant tuberculosis?

75 prevalence of multidrug-resistant tuberculosis and associated factors in ethiopia: a systematic review

76 systematic evaluation of structure-activity relationships of the riminophenazine class and discovery of a c2 pyridylamino series for the treatment of multidrug-resistant tuberculosis

77 trends and characteristics of drug-resistant tuberculosis in rural shandong, china

78 possible impact of the standardized category iv regimen on multidrug-resistant tuberculosis patients in mumbai

79 fluoroquinolone resistance in non-multidrug-resistant tuberculosis—a surveillance study in new south wales, australia, and a review of global resistance rates

80 epidemiology and spatial distribution of cases of multidrug-resistant tuberculosis (mdr-tb) in brazil, 2008-2012

81 risk factors for multidrug-resistant tuberculosis

82 Genotypic Resistance of Pyrazinamide but Not Minimum Inhibitory Concentration Is Associated With Longer Time to Sputum Culture Conversion in Patients With Multidrug-resistant Tuberculosis

83 [In vitro antituberculous activity of ofloxacin and levofloxacin against multidrug-resistant tuberculosis and clinical outcomes].

Keyword Connections

Journals

Research Groups

Bibliographies